GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » Enterprise Value

Athersys (Athersys) Enterprise Value : $17.86 Mil (As of May. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Athersys Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Athersys's Enterprise Value is $17.86 Mil. Athersys's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-41.76 Mil. Therefore, Athersys's EV-to-EBIT ratio for today is -0.43.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Athersys's Enterprise Value is $17.86 Mil. Athersys's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-40.75 Mil. Therefore, Athersys's EV-to-EBITDA ratio for today is -0.44.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Athersys's Enterprise Value is $17.86 Mil. Athersys's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.08 Mil. Therefore, Athersys's EV-to-Revenue ratio for today is 223.24.


Athersys Enterprise Value Historical Data

The historical data trend for Athersys's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Enterprise Value Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 156.72 161.50 302.58 191.55 14.76

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.10 14.76 28.01 41.22 29.12

Competitive Comparison of Athersys's Enterprise Value

For the Biotechnology subindustry, Athersys's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athersys's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Athersys's Enterprise Value falls into.



Athersys Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Athersys's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

Athersys's Enterprise Value for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athersys  (OTCPK:ATHXQ) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Athersys's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=17.859/-41.762
=-0.43

Athersys's current Enterprise Value is $17.86 Mil.
Athersys's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.76 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Athersys's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=17.859/-40.752
=-0.44

Athersys's current Enterprise Value is $17.86 Mil.
Athersys's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.75 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Athersys's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=17.859/0.08
=223.24

Athersys's current Enterprise Value is $17.86 Mil.
Athersys's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athersys Enterprise Value Related Terms

Thank you for viewing the detailed overview of Athersys's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (Athersys) Business Description

Traded in Other Exchanges
N/A
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Executives
Neema Mayhugh director 3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan director 100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo director, officer: Chief Executive Officer ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen officer: Chief Operating Officer 16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado officer: Interim, CFO 485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann officer: President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington director, officer: Chief Scientific Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell officer: Vice President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah director ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub director
Tadahisa Kagimoto director, 10 percent owner HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115